Results 21 to 30 of about 18,546 (173)
Anakinra Removal by Continuous Renal Replacement Therapy: An Ex Vivo Analysis
Critical Care Explorations, 2023 OBJECTIVES:. Patients with sepsis are at significant risk for multiple organ dysfunction, including the lungs and kidneys. To manage the morbidity associated with kidney impairment, continuous renal replacement therapy (CRRT) may be required.
Samuel D.J. Dubinsky, PharmD +7 more
doaj +1 more source
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis
Hepatology, EarlyView., 2022 Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr +19 more
wiley +1 more source
PLoS ONE, 2023 BackgroundIn patients with COVID-19 and baseline soluble urokinase plasminogen receptor plasma (suPAR) levels ≥ 6ng/mL, early administration of anakinra, a recombinant interleukin-1 receptor antagonist, may prevent disease progression and death.
Francesco Vladimiro Segala +8 more
doaj +1 more source
Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome. [PDF]
PLoS ONE, 2013 IL-1 receptor antagonist anakinra is usually highly efficient in Schnitzler syndrome (SS), a rare inflammatory condition associating urticaria, fever, and IgM monoclonal gammopathy.
David Launay +9 more
doaj +1 more source
Anakinra Therapy for Non-cancer Inflammatory Diseases
Frontiers in Pharmacology, 2018 Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL-1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory mediators, including prostaglandins, cytokines, and chemokines. IL-
Giulio Cavalli +3 more
doaj +1 more source
Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease
Global & Regional Health Technology Assessment, 2020 Background: Anakinra, canakinumab and tocilizumab are all effective alternative treatment choice in patients with Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) adult onset Still’s disease (AOSD) compared to canakinumab and ...
Roberto Ravasio +2 more
doaj +1 more source
Anakinra reduces lung inflammation in experimental acute lung injury
Immunity, Inflammation and Disease, 2022 Introduction Acute respiratory distress syndrome (ARDS) is a severe form of acute lung injury (ALI) resulting in life‐threatening hypoxaemia. Although ARDS can be caused by a variety of pathogens or major trauma, it is best known as the major cause of ...
Paul Engeroff +3 more
doaj +1 more source
Protective effect of anakinra on audiovestibular function in a murine model of endolymphatic hydrops
Frontiers in Cellular Neuroscience, 2022 IntroductionMénière’s disease (MD), a common disease in the inner ear, is characterized by an increase in endolymph in the cochlear duct and vestibular labyrinth. The pathophysiology of the condition appears to be the immune response.
Na Zhang +41 more
doaj +1 more source
Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study
Critical Care, 2020 Background A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases.
Emma J. Kooistra +11 more
doaj +1 more source
Outcomes of MIS-C patients treated with anakinra: a retrospective multicenter national study
Frontiers in Pediatrics, 2023 BackgroundThe treatment of multisystem inflammatory syndrome in children unresponsive to first-line therapies (IVIG and/or steroids) is challenging. The effectiveness of IL-1 receptor antagonist, anakinra, is debated.Patients and methodsWe conducted an ...
Francesco Licciardi +19 more
doaj +1 more source